- Arrowhead Expands the Reach of RNAi Therapies to Address Diseases in the Lung - Late-Breaking Clinical Data for ARO-RAGE for Treatment of Asthma Demonstrate Deep and Durable Gene Silencing - Promising Preclinical Data Across Multiple Gene Targets Suggest Potentially Broad Applications for

PASADENA, Calif. --(BUSINESS WIRE)--Sep. 1, 2023-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Citi’s 18 th Annual BioPharma Conference – September 6, 2023 Type: 1-on-1 Investor Meetings European Respiratory

Conference Call and Webcast Today, August 7, 2023 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Aug. 7, 2023-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2023 . The company is hosting a conference call today,

PASADENA, Calif. --(BUSINESS WIRE)--Jul. 24, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2023 , at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 third quarter ended June 30, 2023 .

PASADENA, Calif. --(BUSINESS WIRE)--Jul. 17, 2023-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2 clinical trial of ARO-DUX4, the company’s investigational RNA interference (RNAi) therapeutic being developed as

PASADENA, Calif. --(BUSINESS WIRE)--Jul. 6, 2023-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 4, 2023 , the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 56

PASADENA, Calif. --(BUSINESS WIRE)--Jun. 27, 2023-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for approval to initiate a Phase 1 clinical trial of ARO-SOD1, an RNAi-based investigational medicine designed to reduce expression of superoxide

- Data Presented During Oral Session at EASL 2023 Demonstrate Fazirsiran’s Promising Impact on Key Markers of Liver Disease - AATD-LD is a Rare Genetic Disease Affecting Children and Adults with no Approved Treatments - Takeda and Arrowhead are Advancing Fazirsiran and Actively Enrolling in 160

PASADENA, Calif. --(BUSINESS WIRE)--Jun. 6, 2023-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies Global Healthcare Conference – June 8, 2023 Type: Fireside chat presentation Goldman Sachs 44th Annual

- New Clinical Data on ARO-RAGE Show Continued Dose Response with Single Inhaled Dose of 184 mg Achieving Mean Knockdown of 90% and Max of 95% - Adipose Delivery Platform Achieved Single Dose Target Gene Silencing of Greater than 90% with Six Months of Duration in Non-human Primates - Improved